- Home
- JL vs RDHL Comparison
JL vs RDHL Comparison
Compare JL & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JL
- RDHL
- Stock Information
- Founded
- JL 1985
- RDHL 2009
- Country
- JL Hong Kong
- RDHL Israel
- Employees
- JL N/A
- RDHL N/A
- Industry
- JL
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- JL
- RDHL Health Care
- Exchange
- JL NYSE
- RDHL Nasdaq
- Market Cap
- JL 10.1M
- RDHL 8.6M
- IPO Year
- JL 2024
- RDHL N/A
- Fundamental
- Price
- JL $3.03
- RDHL $6.50
- Analyst Decision
- JL
- RDHL
- Analyst Count
- JL 0
- RDHL 0
- Target Price
- JL N/A
- RDHL N/A
- AVG Volume (30 Days)
- JL 349.3K
- RDHL 21.6K
- Earning Date
- JL 07-31-2024
- RDHL 01-03-2025
- Dividend Yield
- JL N/A
- RDHL N/A
- EPS Growth
- JL N/A
- RDHL N/A
- EPS
- JL 0.26
- RDHL N/A
- Revenue
- JL $28,378,669.00
- RDHL $3,707,000.00
- Revenue This Year
- JL N/A
- RDHL $224.90
- Revenue Next Year
- JL N/A
- RDHL $82.69
- P/E Ratio
- JL $11.70
- RDHL N/A
- Revenue Growth
- JL N/A
- RDHL N/A
- 52 Week Low
- JL $0.23
- RDHL $6.00
- 52 Week High
- JL $29.95
- RDHL $40.50
- Technical
- Relative Strength Index (RSI)
- JL 79.30
- RDHL 38.21
- Support Level
- JL $2.64
- RDHL $6.00
- Resistance Level
- JL $3.04
- RDHL $7.30
- Average True Range (ATR)
- JL 0.32
- RDHL 0.51
- MACD
- JL 0.17
- RDHL -0.09
- Stochastic Oscillator
- JL 71.16
- RDHL 21.10
About JL J-LONG GROUP LIMITED
J-Long Group Ltd is an established distributor in Hong Kong of reflective and non-reflective garment trims including, among others, heat transfers, fabrics, woven labels and tapes, sewing badges, piping, zipper pullers and drawcords. It also offers a wide range of apparel solution services to cater to its customers' needs for reflective and non-reflective garment trims, ranging from market trend analysis, product design and development and production to quality control.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.